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ABSTRACT
Objective: To determine the potential role of N-
terminal pro-B-type natriuretic peptide (NT-proBNP) in
screening for and predicting prognosis in heart failure
by examining diagnosis and survival of patients with a
raised NT-proBNP at screening.
Design: Survival analysis.
Setting: Prospective substudy of the
Echocardiographic Heart of England Screening study
(ECHOES) to investigate 10-year survival in participants
with an NT-proBNP level at baseline.
Participants: 594 participants took part in the
substudy. Records of all participants in the ECHOES
cohort were flagged during the screening phase which
ended on 25 February 1999. All deaths until 25
February 2009 were coded.
Outcome measures: Logistic regression was used to
examine whether NT-proBNP is useful in predicting
heart failure at screening after adjustment for age, sex
and cohort. Kaplan-Meier curves and log rank tests
were used to compare survival times of participants
according to NT-proBNP level. Cox regression was
carried out to assess the prognostic effect of NT-
proBNP after allowing for significant covariates and
receiver operator curves were used to determine test
reliability.
Results: The risk of heart failure increased almost
18-fold when NT-proBNP was 150 pg/mL or above
(adjusted OR=17.7, 95% CI 4.9 to 63.5). 10-year survival
in the general population cohort was 61% (95% CI 48%
to 71%) for those with NT-proBNP ≥150 pg/mL and 89%
(95% CI 84% to 92%) for those below the cut-off at the
time of the initial study. After adjustment for age, sex and
risk factors for heart failure, NT-proBNP level ≥150 pg/mL
was associated with a 58% increase in the risk of death
within 10 years (adjusted HR=1.58, 95% CI 1.09 to 2.30).
Conclusions: Raised NT-proBNP levels, when screening
the general population, are predictive of a diagnosis of
heart failure (at a lower threshold than guidelines for
diagnosing symptomatic patients) and also predicted
reduced survival at 10 years.
INTRODUCTION
Biomarkers can be useful in diagnosis, treat-
ment monitoring and to inform prognosis.1–3
B-type natriuretic peptide (BNP) and
N-terminal pro-BNP (NT-proBNP) are
released by the ventricles of the heart in
response to volume and pressure overload.
BNP relaxes vascular smooth muscle to
reduce ventricular preload and acts on the
kidney to increase sodium excretion and
induce diuresis.4 NT-proBNP is an inactive
fragment of the cleaved pro-BNP molecule.
Both peptides have been investigated for use
in diagnosis of heart failure (HF) and left
ventricular systolic dysfunction (LVSD).5 6
NT-proBNP and BNP assays have been found
to be equally reliable for diagnostic use.7
Raised natriuretic peptide levels have consist-
ently been associated with increased mortal-
ity in patients with HF.8 9 There may also be
a role for these assays in determining prog-
nosis in patients with and without HF.10
The Echocardiographic Heart of England
Screening (ECHOES) study was a large HF
screening study carried out in central
England.11 All ECHOES participants under-
went a detailed initial clinical assessment to
screen for evidence of HF. Diagnosis was
determined after blinded adjudication by a
panel of three HF specialists using all the
clinical and investigation data available from
the screening. All deaths were collated from
Strengths and limitations of this study
▪ The Echocardiographic Heart of England
Screening study (ECHOES) cohort represents a
well-phenotyped group with accurate mortality
data.
▪ Not all participants in the ECHOES cohort had an
N-terminal pro-B-type natriuretic peptide meas-
urement but the characteristics of the subgroup
were similar to the whole cohort so are likely to
be generalisable.
▪ By definition the study reports a long term
follow-up (minimum of 10 years) but over this
time both the diagnostic criteria and manage-
ment of heart failure have changed significantly.
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routine mortality data. We previously reported the
10-year prognosis of all patients in the ECHOES study
according to presence or absence of HF and LVSD.12
This analysis uses data from ECHOES to examine the
role of NT-proBNP in predicting a diagnosis of HF at
screening and also the relationship between NT-proBNP
and survival in the following decade.
METHODS
The original ECHOES study screened a total of 6162
participants from 16 practices in central England. Four
practices were randomly selected from each of the four
socioeconomic groups defined using the Townsend
deprivation score. This resulted in a socioeconomically
diverse population, likely to be representative of the
broader UK population. ECHOES included four separ-
ate cohorts: 3960 patients randomly sampled from the
general population over age 45; 782 patients with a pre-
vious label of HF recorded in general practitioner (GP)
notes; 928 patients on diuretic therapy and 1062 with
known risk factors for heart disease (hypertension, dia-
betes, angina, history of myocardial infarction (MI)).
The four cohorts were stipulated prior to the study and
searches were carried out to find patients in each of
these groups using general practice records. Patients
underwent assessment (history, examination, ECG and
echocardiography) to screen for evidence of HF.
A substudy involving 594 ECHOES participants was
also carried out to investigate the role of NT-proBNP in
diagnosis and prognosis of HF. Fuller methods are avail-
able in an earlier publication11 but in brief, participants
came from four general practices, across the Townsend
scale; 309 were sampled from the general population,
103 with a previous label of HF, 88 on diuretic therapy
and 134 with risk factors of heart disease with some
patients belonging to more than one cohort.
During the ECHOES study, which ran from March
1995 to February 1999, the records of all participants
were flagged by the Office for National Statistics (ONS)
Central Register Office. The ONS has provided details
of the date and cause of death for all ECHOES partici-
pants since then. The final participant in the original
ECHOES cohort was screened on 25 February 1999 and
all deaths up to 25 February 2009 had been notified to
the research team. This allowed an estimate of 10-year
prognosis for patients in ECHOES including those from
the NT-proBNP study. All data from the original
ECHOES cohort were recorded in a restricted access
database. The statistical packages SPSS and Stata V.10
were used to analyse the data.
Analytical methods
Area under the receiver operating curve (AUROC) was
calculated for each cohort to measure the natriuretic
peptide’s performance in predicting HF at screening.
Multiple logistic regression was then performed, using
all cohorts combined, to examine whether BNP was
predictive of HF, after adjustment for the sampling struc-
ture and other significant predictors. Variables in the
final model were selected using the backward elimin-
ation method with significance level set at 0.05.
Variables considered in the analysis included
NT-proBNP, age, sex, body mass index (BMI), smoking
status, blood pressure, individual risk factors for HF
(hypertension, angina, MI, diabetes), symptoms (tired-
ness, shortness of breath, ankle oedema), prescribed
drugs (β-blockers, ACE inhibitors, angiotensin receptor
blockers and diuretics) and whether a previous label of
HF was recoded. Two-way interactions with natriuretic
peptide were also considered. The cohort-related vari-
ables were kept in the final model to allow for the sam-
pling structure. To improve the precision of the
estimates, bootstrapped CIs for ORs were calculated
using 1000 replications.
Survival analysis was carried out by each cohort using
Kaplan-Meier curves to demonstrate survival in those
with an NT-proBNP level ≥150 pg/mL. Log rank tests
were used to compare survival between the different
groups. The mean survival times were calculated rather
than median since data was censored for more than
50% of cases. Estimation of the mean is limited to the
largest survival time if data were censored.
Cox regression was then undertaken, using all 594 par-
ticipants, to assess the prognostic ability of NT-proBNP
after allowing for each cohort and other covariates.
Variables entered into the starting model are as
described previously with the addition of atrial fibrilla-
tion, ejection fraction and significant valve disease.
Fractional polynomials were considered when compar-
ing models of best fit for continuous variables of age,
BMI and blood pressure. The proportional hazards
assumption was tested using Schoenfeld residuals.
RESULTS
NT-proBNP levels were measured in 594 participants
during the ECHOES study. An HF diagnosis was con-
firmed for 7 (8%) of those in the general population
sample; 36 (35%) of those with a previous label of HF;
15 (17%) of those on diuretics and 9 (7%) of those at
high risk. Twenty-three (43%) of all those with an HF
diagnosis had an ejection fraction of less than 40% and
an additional 10 persons (19%) had ejection fraction of
between 40% and 49%.
The baseline characteristics of all participants in the
substudy, broken down by cohort and NT-proBNP
150 pg/mL cut-off, are shown in table 1. Those in the
upper NT-proBNP category were older, had more cardio-
vascular risk factors and took more medication than
those below 150 pg/mL. They also, with exception of
those from the cohort with previous label of HF, had
more symptoms of HF.
The distributions of NT-proBNP in each cohort are
given in table 2. The general population had the lowest
values with more than 75% below 150 pg/mL. Highest
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Table 1 Baseline characteristics of patients in the ECHOES NT-proBNP substudy
Characteristics


























Age at screening (mean
(SD) years)
59.6 (8.7) 71.7 (9.7) 72.2 (9.6) 74.7 (8.4) 63.2 (8.8) 74.1 (9.8) 63.2 (8.7) 70.4 (8.2)
Gender, male 130 (54) 31 (45) 9 (43) 47 (57) 24 (73) 26 (47) 43 (64) 33 (49)
Ever smoked 137 (57) 37 (54) 17 (81) 45 (55) 21 (64) 32 (58) 42 (63) 48 (72)
Body mass index (mean
(SD) kg/m2)
27.0 (4.9) 25.8 (3.8) 31.1 (8.5) 26.6 (4.4) 27.9 (3.5) 26.8 (4.5) 28.4 (4.1) 27.1 (3.8)
Systolic BP (mean (SD)
mm/Hg)
149.3 (20.9) 156.1 (23.3) 162.9 (18.3) 149.2 (26.3) 161.7 (22.6) 154.8 (25.2) 155.2 (18.3) 158.7 (23.4)
Diastolic BP (mean (SD)
mm/Hg)
85.6 (10.9) 83.6 (9.9) 84.4 (9.5) 78.0 (12.6) 91.7 (10.3) 82.4 (14.2) 83.9 (10.1) 83.6 (11.7)
History
Diabetes 9 (4) 6 (9) 4 (19) 14 (17) 3 (9) 8 (15) 24 (36) 12 (18)
Myocardial infarction 5 (2) 7 (10) 4 (19) 26 (32) 2 (6) 8 (15) 16 (24) 36 (54)
Angina 12 (5) 16 (23) 7 (33) 33 (40) 3 (9) 14 (25) 23 (34) 46 (69)
Hypertension 54 (22) 24 (35) 9 (43) 27 (33) 29 (88) 31 (56) 38 (57) 39 (58)
Medication taken
Diuretics 15 (6) 20 (29) 16 (76) 70 (85) 33 (100) 55 (100) 12 (18) 26 (39)
ACE inhibitors 12 (5) 5 (7) 4 (19) 39 (48) 10 (30) 20 (36) 19 (28) 18 (27)
ARBs 3 (1) 0 (0) 1 (5) 7 (9) 0 (0) 1 (2) 2 (3) 0 (0)
β-blockers 14 (6) 19 (28) 2 (10) 9 (11) 5 (15) 8 (15) 17 (25) 21 (31)
Symptoms
Shortness of breath 48 (20) 32 (46) 16 (76) 61 (74) 11 (33) 34 (62) 17 (25) 44 (66)
Tired 70 (29) 33 (48) 15 (71) 62 (75) 12 (36) 35 (64) 27 (40) 42 (63)
Ankle swelling 38 (16) 22 (32) 15 (71) 41 (50) 10 (30) 29 (53) 22 (33) 22 (33)
New York Heart Association class
1 200 (83) 39 (57) 5 (24) 22 (27) 23 (70) 21 (38) 57 (78) 28 (42)
2 35 (15) 23 (33) 11 (52) 30 (37) 7 (21) 21 (38) 10 (15) 29 (43)
3 4 (2) 2 (3) 3 (14) 15 (18) 3 (9) 8 (15) 1 (1) 6 (9)
4 1 (0.4) 5 (7) 2 (10) 15 (18) 0 (0) 5 (9) 4 (6) 4 (6)
Ejection fraction
<40% 1 (0.4) 4 (6) 1 (5) 20 (24) 1 (3) 6 (11) 1 (1) 9 (13)
40–49% 2 (0.8) 3 (4) 2 (10) 18 (22) 1 (3) 6 (11) 3 (4) 6 (9)
≥50% 237 (98.7) 62 (90) 18 (86) 44 (54) 31 (94) 43 (78) 63 (94) 52 (78)
Diagnosis
Definite HF 0 (0) 7 (10) 1 (5) 35 (43) 1 (3) 14 (25) 0 (0) 9 (13)
Atrial fibrillation 0 (0) 7 (10) 0 (0) 23 (28) 0 (0) 13 (24) 0 (0) 3 (4)
Significant valve disease 0 (0) 5 (7) 1 (5) 9 (11) 0 (0) 7 (13) 0 (0) 3 (4)
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levels were observed in the cohort with a previous label
of HF.
Figures 1–4 show the receiver operating curves for
assessing the performance of NT-proBNP in diagnosing
HF in each of the cohorts. The AUROC for NT-proBNP
levels above 150 pg/mL was 0.95 (95% CI 0.88 to 1.00)
for the general population; 0.83 (0.75 to 0.91) for those
with previous label of HF; 0.91 (0.82 to 1.00) for those
on diuretics; and 0.88 (0.80 to 0.97) for those at risk of
HF. The cut-off for NT-proBNP at 150 pg/mL had sensi-
tivity of 100% (95% CI 59% to 100%) and specificity of
79.5% (95% CI 74.5% to 83.9%) in identifying HF in
the general population sample; 97.2% (85.5% to 99.9%)
sensitivity and 29.9% (19.3% to 42.3%) specificity for
those with previous label of HF; 93.3% (68.1% to
99.8%) sensitivity and 43.8% (32.2% to 55.9%) specifi-
city for those on diuretics; and 100% (66.4% to 100%)
sensitivity and 53.6% (44.5% to 62.6%) specificity for
those at high risk. A full summary of performance
characteristics, including positive and negative predictive
values and accuracy is given in table 3. Other cut-offs
were not considered in this analysis due to the high sen-
sitivity and reasonable specificity observed using the
chosen cut-off. Overall, a cut-off of 150 pg/mL found
100% of HF cases and 80% of non-HF cases. The per-
centage of deaths at 10 years with NT-proBNP
≥150 pg/mL at baseline was 50% in the general
population, 86% in HF label group, 71% in the high-risk
group and 84% in the diuretics group.
The multiple logistic regression analysis suggests that
NT-proBNP≥150 pg/mL is predictive of HF (OR=17.7
(95% CI 4.9 to 63.5)) after allowing for cohort related
variables (table 4).
Cause of death
Cardiovascular disease was the main cause of death in
each cohort, ranging from 31% (95% CI 20% to 46%)
in the general population to 49% (95% CI 37% to 61%)
in the high-risk group. The remaining deaths were
mainly due to respiratory disease and cancer.
Survival analysis of the general population cohort
There was a statistically significant difference in survival
between those who had an NT-proBNP level ≥150 pg/
mL and those with an NT-proBNP level <150 pg/mL in
the general population sample (log-rank test, χ2=30.4, 1,
p<0.0001) as shown in figure 5. Mean survival for those
Table 2 Distribution of NT-proBNP in each cohort
Cohort N Median (IQR)
General population 309 70.9 (35.3–130.1)
Previous label of HF 103 493.6 (204.3–1341)
On diuretics 88 200 (76.1–672.8)
At high risk 134 160.1 (64.6–386.3)
HF, heart failure; NT-proBNP, N-terminal pro-B-type natriuretic
peptide.
Figure 2 Receiver operating characteristic curve to show
effectiveness of baseline N-terminal pro-B-type natriuretic
peptide (NT-proBNP) in predicting a diagnosis of heart failure
at screening in the ‘previous label of heart failure’ cohort.
Figure 1 Receiver operating characteristic curve to show
effectiveness of baseline N-terminal pro-B-type natriuretic
peptide (NT-proBNP) in predicting a diagnosis of heart failure
at screening in the general population cohort.
Figure 3 Receiver operating characteristic curve to show
effectiveness of baseline N-terminal pro-B-type natriuretic
peptide (NT-proBNP) in predicting a diagnosis of heart failure
at screening in the ‘prescribed diuretics’ cohort.
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with an NT-proBNP ≥150 pg/mL was 8.7 years (95% CI
8.0 to 9.4) compared to 9.9 years (95% CI 9.7 to 10.2)
for those with an NT-proBNP<150pg/mL. Ten-year sur-
vival was 61% (95% CI 48% to 71%) for those with an
NT-proBNP ≥150 pg/mL and 89% (95% CI 84% to
92%) for those with NT-proBNP <150 pg/mL at the
time of the initial study.
Survival analysis of the other cohorts
Reduced length of survival was also observed for those
above the NT-proBNP cut-off when compared with those
below the cut-off in each of the other cohorts (p<0.001).
Those sampled with a previous label of HF and with
NT-proBNP ≥150pg/mL had a mean survival of 5.8 years
(95% CI 5.0 to 6.5) compared to 8.4 years (95% CI 7.1 to
9.7) for those below the cut-off (figure 6). The compara-
tive results for those on diuretics (figure 7) were 7.0 years
(6.0–7.9) vs 9.5 years (8.7–10.4); and those at high risk
(figure 8) 8.3 years (7.6–9.0) versus 9.4 years (8.8–10.0).
Cox regression analysis of all cohort data
Table 5 shows a cox regression model examining factors
associated with mortality using data from all four
cohorts. After adjustment for demographic variables and
shortness of breath, NT-proBNP ≥150 pg/mL was found
to increase the risk of death by 58% (HR=1.58 (1.09–
2.30)).
DISCUSSION
Summary of main findings
In total 594 participants of the ECHOES study took part
in the NT-proBNP substudy. Mean survival time for parti-
cipants from the general population with an NT-proBNP
≥150 pg/mL was over 1 year less than participants with
NT-proBNP <150 pg/mL (8.7 vs 9.9 years). The propor-
tion of patients surviving 10 years was significantly lower
in the group with an NT-proBNP level ≥150 pg/mL
compared to an NT-proBNP level <150pg/mL (61% vs
Figure 4 Receiver operating characteristic curve to show
effectiveness of baseline N-terminal pro-B-type natriuretic
peptide (NT-proBNP) in predicting a diagnosis of heart failure
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89%, respectively in the general population). An
NT-proBNP level ≥150 pg/mL was strongly predictive of
a diagnosis of HF at screening and of death in the next
10 years.
Strengths and limitations of the study
The ECHOES study represents a unique cohort of
patients with well phenotyped HF from a community
setting. The rigour of clinical assessment means the
diagnosis of HF is accurate. All participants’ notes were
flagged by ONS to ensure accurate data about date and
cause of death, and were sent to the research team. The
ONS records reflect the reason for death in the opinion
of the attending clinician, as recorded on the death cer-
tificate, but the symptoms of HF can be similar to other
conditions, particularly respiratory disorders and clini-
cians can disagree. The study design also did not allow
for interim data collection so non-fatal end points, such
as hospitalisation, were not explored.
NT-proBNP levels were not recorded in all participants
of the ECHOES study however the baseline character-
istics of the NT-proBNP substudy were similar to those of
the study population as a whole. Only 3% of participants
were non-white which may not fully reflect the ethnic
diversity of the UK population and NT-proBNP levels
may vary depending on ethnicity. Renal function was not
recorded in this study therefore we were unable to assess
the effect of renal impairment on mortality.13 A cut-off
of 150 pg/mL was chosen to represent a raised level of
NT-proBNP in the substudy however debate exists
around the optimal cut-off level for NT-proBNP.14
The study reports a long-term follow-up of 10 years and
over this time the diagnostic criteria and management of
HF have changed significantly. The original diagnosis of
HF in the ECHOES study was based on the European
Society of Cardiology guideline 1995 and this definition
has been updated several times since then.15–17 At the
time, HF with reduced ejection fraction was the main
recognised type of HF and the most common precursor
to this was, and remains, ischaemic heart disease.
Sixty-nine per cent of the HF-labelled group in this study
had a history of angina or MI. In the past 10–15 years, HF
with preserved ejection fraction, or HF-PEF, has also been
recognised as a distinct clinical and pathological entity.
The atrial fibrillation and/or significant valve disease
groups (with normal ejection fraction) in the ECHOES
Table 4 Logistic regression model to predict HF
Variable OR (95% CI*) p Value
Previous label of HF 3.74 (1.45 to 9.69) 0.007
On diuretics 5.26 (1.70 to 16.31) 0.004
Diabetes 4.91 (1.66 to 14.51) 0.004
Hypertension 0.39 (0.16 to 0.97) 0.04
Angina 1.22 (0.99 to 5.00) 0.053
Myocardial infarction 1.61 (0.67 to 3.86) 0.29
NT-proBNP ≥150 pg/mL 17.65 (4.91 to 63.48) <0.001
*Bootstrapped estimates.
HF, heart failure; NT-proBNP, N-terminal pro-B-type natriuretic
peptide.
Figure 6 Kaplan-Meier curve showing N-terminal pro-B-type
natriuretic peptide (NT-proBNP) level and ten year survival
for the cohort with a previous label of heart failure.
Figure 5 Kaplan-Meier curve showing N-terminal pro-B-type
natriuretic peptide (NT-proBNP) level and ten year survival for
the general population cohort.
Figure 7 Kaplan-Meier curve showing N-terminal pro-B-type
natriuretic peptide (NT-proBNP) level and ten year survival for
the diuretic cohort.
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study may have partly captured some patients with
HFPEF but this group will have largely been excluded.
The ECHOES-extension study has rescreened the entire
cohort, phenotyping for HF-REF and HF-PEF and will
report shortly.
Comparison with existing literature
A study by Wang et al8 investigated the relationship
between BNP levels and risk of cardiovascular events or
death in 3346 patients from the Framingham cohort
who did not have HF at baseline. In total 119 partici-
pants died and 79 had a first cardiovascular event
during a mean follow-up of 5.2 years. For each 1 SD
increment increase in log BNP level, risk of developing
HF increased by 77% (p<0.001) and risk of death
increased by 27% (p=0.009).
BNP and NT-proBNP levels also increase with HF
stage. A study of patients over the age of 45 from the
Rochester Epidemiology Study found that mean BNP
(rather than NT-proBNP) level was 26 pg/mL in patients
without HF, 32 pg/mL in those with risk factors, 53 pg/
mL in those asymptomatic participants with structural or
functional cardiac abnormalities, 137 pg/mL in partici-
pants with HF symptoms and 353 pg/mL for participants
with severe HF. Survival declined progressively for each
additional stage of disease.18
Another study by Hartmann et al9 investigated the role
of baseline NT-proBNP in predicting mortality and hos-
pitalisation in patients with a diagnosis of HF.
NT-proBNP levels were recorded in 814 men and 197
women with severe HF defined as breathlessness at rest
or on minimal exertion and an ejection fraction of less
than 25%. They were followed up for a median time of
159 days (range 1–488 days). A baseline NT-proBNP
level above compared to below the median level for the
cohort was a strong predictor of all-cause mortality and
hospitalisation for HF (relative risk 2.4; 95% CI 1.8 to
3.4; p=0.0001). NT-proBNP has also been found to be
an independent predictor of mortality in patients with
renal disease.10
Overall, participants labelled with HF in the ECHOES
cohort had a better prognosis than some other
community-based studies.19 20 This may reflect a lower
overall risk in the studied population, the introduction
of medication known to improve survival, such as ACE
inhibitors or β-blockers, following screening or a referral
bias in that patients in the study may have been more
likely to be referred for more intensive HF management.
A letter was sent to GPs of all study participants with
advice on management of participants with a confirmed
diagnosis of HF.
Implications for future research and practice
In this substudy, participants with a raised NT-proBNP
level were more likely to have a confirmed diagnosis of
HF after screening. Natriuretic peptides are already used
in clinical practice to determine the likelihood of HF
and guide referral for echocardiography however the
optimal cut-off level is still unclear.17 21 The National
Institute for Health and Care Excellence (NICE) clinical
guideline on the management of chronic HF recom-
mends an NT-proBNP of 400 pg/mL is used as the
threshold to refer for echocardiography in symptomatic
patients, whereas the European Society of Cardiology
suggests a threshold level of 125 pg/mL to exclude HF.
Fuat et al22 showed that a cut-off of 150 pg/mL had a
negative predictive value of 92% in a primary care com-
munity HF clinic, again in symptomatic patients. Our
data suggest that the current NICE cut-off is too high
and that 150 pg/mL is a more reliable threshold for
further investigation, especially since our data include
asymptomatic as well as symptomatic non-presenting
patients.
Importantly, participants in the NT-proBNP substudy
with a raised NT-proBNP were also more likely to die
sooner than participants with a normal NT-proBNP
level. These data confirm the potential for incident
NT-proBNP tests to indicate patient prognosis in
primary care settings as has been confirmed in hospital
Figure 8 Kaplan-Meier curve showing N-terminal pro-B-type
natriuretic peptide (NT-proBNP) level and 10 year survival for
the high risk cohort.
Table 5 Cox regression model of factors associated with
mortality (including all study cohorts)
Variable HR (95% CI*) p Value
Age 1.10 (1.08 to 1.10) <0.001
Male sex 2.05 (1.43 to 2.95) <0.001
Previous label of HF 1.75 (1.17 to 2.57) 0.007
On diuretics 0.90 (0.62 to 1.32) 0.59
Diabetes 1.08 (0.65 to 1.88) 0.78
Hypertension 1.37 (0.99 to 1.90) 0.06
Angina 1.04 (0.73 to 1.50) 0.82
Myocardial infarction 1.18 (0.80 to 1.73) 0.40
Shortness of breath 1.64 (1.14 to 2.37) 0.008
NT-proBNP ≥150 pg/mL 1.58 (1.09 to 2.30) 0.02
*Bootstrapped estimates.
HF, heart failure; NT-proBNP, N-terminal pro-B-type natriuretic
peptide.
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settings. Assessment of patients to establish the cause of
a raised NT-proBNP level such as HF or renal disease fol-
lowed by optimal management using evidence-based
therapies is crucial to reducing mortality in these high-
risk patients.
Finally, these data are the first we are aware of that
suggest a possible role for natriuretic peptides in popula-
tion screening for HF. Given the late diagnosis in many
patients and the asymptomatic nature in early stages,
this may be an important finding.
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